Abeona Therapeutics reports Q2 EPS (49c), consensus (35c).
Cash, cash equivalents and marketable securities as of June 30, 2019, were $62.5M compared to $68.3M as of March 31, 2019. The decrease in cash was driven primarily by the net cash used in operating activities of $15.2M. "The second quarter was highlighted by progress made in both of our MPS III programs," said Joao Siffert, M.D., Chief Executive Officer. "Data from our Transpher A study showed that children with MPS IIIA who were treated early with ABO-102 preserved neurocognitive development within the normative range 12-18 months post treatment. Our MPS IIIB program has also progressed, with enrollment of additional patients in cohort 2 of the Transpher B study. Our team remains highly focused on our lead programs, including the start of our VIITAL Phase 3 clinical trial in recessive dystrophic epidermolysis bullosa, continued enrollment in the MPS III programs, and preparations to start the clinical trial in CLN1 disease."
|Printer friendly Cite/link Email Feedback|
|Article Type:||Financial report|
|Date:||Aug 9, 2019|
|Previous Article:||Amgen 'pleased' with decision in Sandoz patent case.|
|Next Article:||J. Alexander's expands review of strategic alternatives.|